In the BioHarmony Drug Report Database

"Preview" Icon

Tagraxofusp-erzs

Elzonris (tagraxofusp) is a protein pharmaceutical. Tagraxofusp was first approved as Elzonris on 2018-12-21. It is used to treat malignant histiocytic disorders in the USA. It has been approved in Europe to treat lymphoma.

 

Trade Name

 

Elzonris
 

Common Name

 

tagraxofusp
 

ChEMBL ID

 

CHEMBL4297573
 

Indication

 

lymphoma, malignant histiocytic disorders
 

Drug Class

 

Fusion proteins

Image (chem structure or protein)

Tagraxofusp-erzs structure rendering